Alnylam Pharmaceuticals (ALNY) Accumulated Expenses (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Accumulated Expenses came in at $1.1 billion in Q2 2026, up 19.26% YoY from $919.0 million in Q2 2025, and up 15.79% on a QoQ basis from $946.5 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Accumulated Expenses (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Accumulated Expenses data on file, last reported at $1.1 billion in Q2 2026.
- Quarterly Accumulated Expenses rose 19.26% year-over-year to $1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.1 billion (up 19.26% YoY) and the FY2025 annual result came in at $1.1 billion, up 36.1% from the prior year.
- Accumulated Expenses rose to $1.1 billion in Q2 2026, from $946.5 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $1.2 billion in Q3 2025 to a low of $355.9 million in Q1 2022.
- A 5-year average of $750.7 million and a median of $713.1 million in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 42.89% — and 2025, when it advanced 0.76%.
- Tracing ALNY's Accumulated Expenses over 5 years: stood at $545.5 million in 2022, then surged by 30.72% to $713.0 million in 2023, then grew by 11.32% to $793.7 million in 2024, then soared by 36.1% to $1.1 billion in 2025, then advanced by 1.46% to $1.1 billion in 2026.
- The last three Accumulated Expenses figures came in at $1.1 billion (Q2 2026), $946.5 million (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Bn |
| Mar 31, 2026 | 946.49 Mn |
| Dec 31, 2025 | 1.08 Bn |
| Sep 30, 2025 | 1.15 Bn |
| Jun 30, 2025 | 918.97 Mn |
| Mar 31, 2025 | 704.17 Mn |
| Dec 31, 2024 | 793.69 Mn |
| Sep 30, 2024 | 946.17 Mn |
| Jun 30, 2024 | 808.64 Mn |
| Mar 31, 2024 | 698.87 Mn |
| Dec 31, 2023 | 713.01 Mn |
| Sep 30, 2023 | 713.09 Mn |
| Jun 30, 2023 | 598.53 Mn |
| Mar 31, 2023 | 508.60 Mn |
| Dec 31, 2022 | 545.46 Mn |
| Sep 30, 2022 | 510.58 Mn |
| Jun 30, 2022 | 421.24 Mn |
| Mar 31, 2022 | 355.94 Mn |
| Dec 31, 2021 | 395.17 Mn |
| Sep 30, 2021 | 388.58 Mn |